Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.84 -0.3%	$4.97	$1.14 ▼ $7.20	$349.82M	0.8	825,906 shs	453,141 shs
BNTC Benitec Biopharma	$13.24 +1.6%	$12.37	$8.06 ▼ $17.15	$347.55M	0.43	40,797 shs	45,169 shs
CTMX CytomX Therapeutics	$2.04 -0.5%	$2.24	$0.40 ▼ $3.10	$336.42M	2.18	3.91 million shs	1.21 million shs
QNCX Quince Therapeutics	$1.60 +3.9%	$1.67	$0.66 ▼ $2.45	$85.94M	0.99	202,930 shs	224,871 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+0.52%	+21.41%	+175.47%	+1.48%
BNTC Benitec Biopharma	0.00%	+1.92%	+20.80%	-15.18%	+43.21%
CTMX CytomX Therapeutics	0.00%	-3.77%	-13.19%	-18.73%	+72.88%
QNCX Quince Therapeutics	0.00%	-1.84%	-4.76%	+50.94%	+131.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	1.8054 of 5 stars	3.3	1.0	0.0	2.2	1.7	0.6
BNTC Benitec Biopharma	1.5415 of 5 stars	3.6	1.0	0.0	2.7	0.8	0.0
CTMX CytomX Therapeutics	4.1888 of 5 stars	3.5	1.0	4.7	3.1	1.7	1.3
QNCX Quince Therapeutics	3.6753 of 5 stars	4.6	3.0	0.0	4.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.67	Moderate Buy	$9.50	62.67% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	96.37% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.75	181.86% Upside
QNCX Quince Therapeutics	3.18	Buy	$8.14	408.93% Upside

Current Analyst Ratings Breakdown

Latest QNCX, CTMX, ALDX, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
8/12/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$9.00 ➝ $8.00
8/8/2025	ALDX Aldeyra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/5/2025	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/5/2025	QNCX Quince Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
8/5/2025	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$9.00
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/17/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/13/2025	QNCX Quince Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
BNTC Benitec Biopharma	$80K	4,344.38	N/A	N/A	$4.68 per share	2.83
CTMX CytomX Therapeutics	$138.10M	2.44	$0.36 per share	5.64	($0.01) per share	-204.00
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	$0.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	11/6/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.56	3.64	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
QNCX Quince Therapeutics	-$56.83M	-$1.09	N/A	N/A	N/A	N/A	-187.49%	-42.47%	11/12/2025 (Estimated)

Latest QNCX, CTMX, ALDX, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2025	Q4 2025	BNTC Benitec Biopharma	-$0.24	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	QNCX Quince Therapeutics	-$0.28	-$0.34	-$0.06	-$0.34	N/A	N/A
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
BNTC Benitec Biopharma	0.01	14.80	14.80
CTMX CytomX Therapeutics	N/A	4.20	4.20
QNCX Quince Therapeutics	1.45	5.00	5.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
BNTC Benitec Biopharma	52.19%
CTMX CytomX Therapeutics	67.77%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	8.50%
BNTC Benitec Biopharma	1.30%
CTMX CytomX Therapeutics	6.60%
QNCX Quince Therapeutics	16.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.81 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
QNCX Quince Therapeutics	60	53.71 million	44.69 million	Optionable

QNCX, CTMX, ALDX, and BNTC Headlines

Recent News About These Companies

Quince Therapeutics (NASDAQ:QNCX) Raised to "Hold" at Zacks Research

August 30 at 6:31 AM | marketbeat.com

Quince Therapeutics Inc News (QNCX) - Investing.com

August 22, 2025 | investing.com

QNCX Q3 EPS Estimate Lifted by Brookline Capital Management

August 17, 2025 | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Receives "Buy" Rating from D. Boral Capital

August 17, 2025 | marketbeat.com

QNCX FY2029 EPS Increased by Brookline Capital Management

August 16, 2025 | marketbeat.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from Brokerages

August 16, 2025 | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Price Target Cut to $8.00 by Analysts at JMP Securities

August 13, 2025 | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

August 12, 2025 | marketbeat.com

Quince Therapeutics price target lowered to $8 from $9 at Citizens JMP

August 12, 2025 | msn.com

Quince Therapeutics Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 11, 2025 | businesswire.com

Quince Therapeutics (QNCX) Projected to Post Earnings on Tuesday

August 6, 2025 | marketbeat.com

JMP Securities Begins Coverage on Quince Therapeutics (NASDAQ:QNCX)

August 6, 2025 | marketbeat.com

Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Citizens Jmp

August 6, 2025 | marketbeat.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Up 64.5% in July

August 6, 2025 | marketbeat.com

JMP Securities Initiates Coverage of Quince Therapeutics (QNCX) with Market Outperform Recommendation

August 5, 2025 | msn.com

Quince Therapeutics, Inc. (QNCX) - Yahoo Finance

July 17, 2025 | finance.yahoo.com

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

July 16, 2025 | businesswire.com

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan ...

July 12, 2025 | finance.yahoo.com

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

July 10, 2025 | businesswire.com

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

June 25, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, CTMX, ALDX, and BNTC Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.84 -0.02 (-0.34%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.90 +0.07 (+1.11%)

As of 08/29/2025 07:40 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Benitec Biopharma NASDAQ:BNTC

$13.24 +0.21 (+1.61%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$13.64 +0.40 (+3.06%)

As of 08/29/2025 05:16 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

CytomX Therapeutics NASDAQ:CTMX

$2.04 -0.01 (-0.49%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.05 +0.01 (+0.54%)

As of 08/29/2025 07:50 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Quince Therapeutics NASDAQ:QNCX

$1.60 +0.06 (+3.90%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.56 -0.04 (-2.44%)

As of 08/29/2025 05:36 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time